OR WAIT null SECS
February 04, 2022
Domainex is collaborating with Parkinson’s UK for the development of small-molecule therapies targeting the neuroinflammation that is associated with Parkinson’s disease.
ABPI has responded to the publication of a white paper on ‘Levelling Up’ by the government of the United Kingdom.
Zetta Genomics has raised £2.5 million ($3.4 million) in new seed funding.
Janssen has submitted a MAA to the EMA for teclistamab as a treatment of relapsed or refractory multiple myeloma (RRMM).
pharmasol has completed the strategic merger with PharmaLex.
Pharming Group has announced positive results from the Phase II/III study of leniolisib for the treatment of activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS).
The UK’s NICE issued a Final Appraisal Document recommending marketing authorization for AstraZeneca’s chronic kidney disease treatment, Forxiga (dapagliflozin).
February 01, 2022
Recipharm will build up its biologics service offering with the acquisition of GenIbet.
January 28, 2022
Scottish biotech engineering company, uFraction8, has successfully secured more than £2.5 million ($3.3 million) in new investment.
NICE has updated its Technology Appraisal Guidance TA599 for AstraZeneca’s Lokelma.